pISSN 2234-3806eISSN 2234-3814
Table. 1.
Clinicopathological characteristics of patients with non-cryptic NUP98 rearrangement
| Case No. | Age (yrs) | Sex | WBC(×109/L) | Hb(g/L) | PLT(×109/L) | Diagnosis | Etiology | FAB classification | Immunophenotype | Dysplasia (lineage) | CR | Allogeneic PBSCT | RFS | Outcome(OS) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | M | 5.75 | 68 | 34 | AML | de novo | M5 | CD11c+, CD13+, CD33+, CD34+dim, CD64+dim, CD117+, cMPO+, HLA-DR+ | + (E/M) | + | + | +(12 mo) | D(23 mo) |
| 2 | 45 | M | 95.13 | 84 | 40 | AML | de novo | M5 | CD13+, CD33+, CD64+, CD117+dim, cMPO+, HLA-DR+ | + (M) | + | + | –(41 mo) | A(42 mo) |
| 3 | 50 | F | 2.47 | 100 | 56 | MDS | therapy-related (OC) | NA | NA | – | NA | – | – | D(5 mo) |
| 4 | 37 | F | 214.37 | 74 | 38 | CMML-2; AML (28 mo) |
de novo | M5 | CD11c+dim, CD13+, CD33+, CD34+ | + (E/G/M) | + | + | +(12 d) | D(32 mo) |
| 5 | 77 | F | 15.68 | 61 | 4 | AML | therapy-related (OC) | M5 | CD13+, CD33+, CD64+, CD66c+, CD117+, cMPO+ | + (E) | NA | – | – | D(4 mo) |
| 6 | 58 | F | 2.54 | 98 | 96 | AML | de novo | M1 | CD13+, CD33+, CD34+, CD117+, cMPO+, HLA-DR+ | – | + | + | –(106 mo) | A(107 mo) |
| 7 | 55 | F | 3.31 | 98 | 154 | MDS-EB2; AML (4 mo) |
de novo | M5 | CD4+dim, CD11c+dim, CD13+, CD33+, CD64+, CD117+, cMPO+, HLA-DR+, nTdT+dim | + (E/G) | + | – | –(6 mo) | D(12 mo) |
| 8 | 14 | M | 82.44 | 121 | 26 | AML | de novo | M1 | CD7+, CD13+, CD33+, CD34+, cMPO+ | – | NA | – | – | D(3 d) |
| 9 | 60 | F | 1.29 | 67 | 5 | AML | therapy-related (OC) | M1 | CD7+, CD13+, CD33+, CD34+dim, CD64+, CD117+, cMPO+, HLA-DR+ | – | NA | – | – | D(30 d) |
| 10 | 29 | F | 233.81 | 98 | 70 | AML | de novo | M4 | CD2+dim, CD11c+, CD13+, CD19+dim, CD33+, CD34+, CD64+dim, cCD79a+dim, CD117+, cMPO+, HLA-DR+, nTdT+dim | + (M) | + | + | +(4 mo) | D(8 mo) |
| 11 | 58 | M | 6.68 | 85 | 573 | AML | de novo | M4 | CD13+, CD14–/+, CD33+, CD34+/+dim, CD64–/+, CD117+/–, cMPO+, HLA-DR+ | + (G/M) | + | + | +(5 mo) | D(13 mo) |
*Time to leukemic transformation.
Abbreviations: WBC, white blood cell; PLT, platelet; FAB, French-American-British; CR, complete remission; PBSCT, peripheral blood stem cell transplantation; RFS, relapse-free survival; OS, overall survival; M, male; F, female; aE, erythroid; M, megakaryocytic; G, granulocytic; D, dead; A, alive; mo, months; d, days; NA, not available; MDS, myeloid dysplastic neoplasm; CMML, chronic myelomonocytic leukemia; MDS-EB2, MDS with excess blasts; OC, ovarian cancer; BC, breast cancer.
Ann Lab Med 2025;45:53~61 https://doi.org/10.3343/alm.2024.0190
© Ann Lab Med